CA2457982C - Use of nefiracetam for treating neurodegeneration - Google Patents

Use of nefiracetam for treating neurodegeneration Download PDF

Info

Publication number
CA2457982C
CA2457982C CA002457982A CA2457982A CA2457982C CA 2457982 C CA2457982 C CA 2457982C CA 002457982 A CA002457982 A CA 002457982A CA 2457982 A CA2457982 A CA 2457982A CA 2457982 C CA2457982 C CA 2457982C
Authority
CA
Canada
Prior art keywords
stroke
nefiracetam
months
post
recovery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002457982A
Other languages
English (en)
French (fr)
Other versions
CA2457982A1 (en
Inventor
Eiichi Otomo
Yoshiyuki Takasu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hamilton Pharmaceuticals Inc
Original Assignee
Hamilton Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hamilton Pharmaceuticals Inc filed Critical Hamilton Pharmaceuticals Inc
Publication of CA2457982A1 publication Critical patent/CA2457982A1/en
Application granted granted Critical
Publication of CA2457982C publication Critical patent/CA2457982C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CA002457982A 2001-08-22 2001-08-22 Use of nefiracetam for treating neurodegeneration Expired - Fee Related CA2457982C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2001/007180 WO2003018005A1 (en) 2001-08-22 2001-08-22 use of nefiracetam for treating neurodegeneration

Publications (2)

Publication Number Publication Date
CA2457982A1 CA2457982A1 (en) 2003-03-06
CA2457982C true CA2457982C (en) 2009-11-03

Family

ID=11737657

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002457982A Expired - Fee Related CA2457982C (en) 2001-08-22 2001-08-22 Use of nefiracetam for treating neurodegeneration

Country Status (8)

Country Link
US (2) US20040192759A1 (enExample)
EP (1) EP1420782B1 (enExample)
JP (1) JP2005501108A (enExample)
AT (1) ATE404192T1 (enExample)
CA (1) CA2457982C (enExample)
DE (1) DE60135390D1 (enExample)
ES (1) ES2311537T3 (enExample)
WO (1) WO2003018005A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060241144A1 (en) * 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
RU2329804C2 (ru) * 2006-03-28 2008-07-27 Валентина Ивановна Ахапкина Вещество, обладающее нейротропной - нейромодуляторной активностью
BRPI0920342A2 (pt) * 2008-10-16 2020-06-23 The Johns Hopkins University Uso de um inibidor da proteína vesicular sináptica 2a (sv2a) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica para melhora da função cognitiva, uso de levitiracetam ou um sal farmaceuticamente aceitável do mesmo, uso de brivaracetam ou um sal farmaceuticamente aceitável do mesmo, uso do seletracetam ou um sal farmaceuticamente aceitável do mesmo
US8962676B2 (en) 2009-10-22 2015-02-24 University College Dublin, National University Of Ireland, Dublin Causal therapy of diseases or conditions associated with CNS or PNS demyelination
EP2533645B1 (en) * 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
CN107810002B (zh) 2015-05-22 2021-01-05 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749700A (en) * 1984-10-23 1988-06-07 Nastech Pharmaceutical Co, Inc. Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same
SK279285B6 (sk) * 1991-05-02 1998-09-09 Daiichi Pharmaceutical Co. Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin
JP3388778B2 (ja) * 1991-05-02 2003-03-24 第一製薬株式会社 脳血管性痴呆改善剤
AU8131198A (en) * 1997-07-15 1999-02-10 Daiichi Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for amnesia
JPH1180027A (ja) * 1997-09-12 1999-03-23 Dai Ichi Seiyaku Co Ltd 向知性薬
US6423739B1 (en) * 2000-02-23 2002-07-23 Daiichi Pharmaceutical Co., Ltd. Method for aiding cerebral recovery following neurodegeneration

Also Published As

Publication number Publication date
US20080076820A1 (en) 2008-03-27
US20040192759A1 (en) 2004-09-30
JP2005501108A (ja) 2005-01-13
EP1420782A1 (en) 2004-05-26
CA2457982A1 (en) 2003-03-06
EP1420782B1 (en) 2008-08-13
ES2311537T3 (es) 2009-02-16
DE60135390D1 (de) 2008-09-25
WO2003018005A1 (en) 2003-03-06
ATE404192T1 (de) 2008-08-15

Similar Documents

Publication Publication Date Title
US20080076820A1 (en) Method for treating neurodegeneration
AU706735B2 (en) Use of 2-amino-4-(4-fluorobenzylamino)-1-ethoxy- carbonylaminobenzene for prophylaxis and treatment of sequelae of acute and chronic reduced circulation in the brain and neurodegenerative disorders
SK4862000A3 (en) The use of 5-ht3 receptor antagonists
EP1435943B1 (en) Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug for treating dyskinesia
US6043251A (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyr idine for preparing drugs for treating amyotrophic lateral sclerosis
CA2368352C (en) Method for treating neurodegeneration
RU2413510C2 (ru) Профилактический или терапевтический агент против депрессии или тревожного расстройства
US6420388B1 (en) Osanetant in the treatment of depression and depressive disorders
KR100692235B1 (ko) 안지오텐신 ⅱ 길항물질의 신규한 용도
DK166755B1 (da) Farmaceutisk praeparat indeholdende en angiotensin-omdannende enzym-inhibitor og et sloejfediuretikum og fremgamgsmaade til fremstilling af praeparatet
US20080021016A1 (en) Combined Pharmaceutical Composition for the Inhibition of the Decline of Cognitive Functions
SK1272003A3 (en) Medicaments containing cilansetron for treating non-obstipated male IBS patients
JPH03209355A (ja) アリールアルキルアミド含有の神経変性疾患治療剤
KR930004646B1 (ko) 심기능 부전의 예방 및 치료제
WO2020014072A1 (en) Neostigmine pharmaceutical combination for treating myasthenia gravis
JPH08512305A (ja) 神経変性疾患の治療を目的とする医薬生成物の製造のためのエファロキサンおよびその誘導体の使用
HU190714B (en) Process for the preparation of pharmaceutical compositions containing dibenzocycloheptadiene antidepressant and ergot alkaloid

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140822